share_log

Piper Sandler Downgrades ImmunityBio to Neutral, Lowers Price Target to $4

Benzinga ·  May 12, 2023 17:27

Piper Sandler analyst Joseph Catanzaro downgrades ImmunityBio (NASDAQ:IBRX) from Overweight to Neutral and lowers the price target from $10 to $4.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment